Now showing items 1-1 of 1

    • A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. 

      Scott, RA; Freitag, DF; Li, L; Chu, AY; Surendran, P; Young, R; Grarup, N; Stancáková, A; Chen, Y; Varga, TV; Yaghootkar, H; Luan, J; Zhao, JH; Willems, SM; Wessel, J; Wang, S; Maruthur, N; Michailidou, K; Pirie, A; van der Lee, SJ; Gillson, C; Al Olama, AA; Amouyel, P; Arriola, L; Arveiler, D; Aviles-Olmos, I; Balkau, B; Barricarte, A; Barroso, I; Garcia, SB; Bis, JC; Blankenberg, S; Boehnke, M; Boeing, H; Boerwinkle, E; Borecki, IB; Bork-Jensen, J; Bowden, S; Caldas, C; Caslake, M; Cupples, LA; Cruchaga, C; Czajkowski, J; den Hoed, M; Dunn, JA; Earl, HM; Ehret, GB; Ferrannini, E; Ferrieres, J; Foltynie, T; Ford, I; Forouhi, NG; Gianfagna, F; Gonzalez, C; Grioni, S; Hiller, L; Jansson, JH; Jørgensen, ME; Jukema, JW; Kaaks, R; Kee, F; Kerrison, ND; Key, TJ; Kontto, J; Kote-Jarai, Z; Kraja, AT; Kuulasmaa, K; Kuusisto, J; Linneberg, A; Liu, C; Marenne, G; Mohlke, KL; Morris, AP; Muir, K; Müller-Nurasyid, M; Munroe, PB; Navarro, C; Nielsen, SF; Nilsson, PM; Nordestgaard, BG; Packard, CJ; Palli, D; Panico, S; Peloso, GM; Perola, M; Peters, A; Poole, CJ; Quirós, JR; Rolandsson, O; Sacerdote, C; Salomaa, V; Sánchez, MJ; Sattar, N; Sharp, SJ; Sims, R; Slimani, N; Smith, JA; Thompson, DJ; Trompet, S; Tumino, R; van der A, DL; van der Schouw, YT; Virtamo, J; Walker, M; Walter, K; Abraham, JE; Amundadottir, LT; Aponte, JL; Butterworth, AS; Dupuis, J; Easton, DF; Eeles, RA; Erdmann, J; Franks, PW; Frayling, TM; Hansen, T; Howson, JM; Jørgensen, T; Kooner, J; Laakso, M; Langenberg, C; McCarthy, MI; Pankow, JS; Pedersen, O; Riboli, E; Rotter, JI; Saleheen, D; Samani, NJ; Schunkert, H; Vollenweider, P; O'Rahilly, S; Deloukas, P; Danesh, J; Goodarzi, MO; Kathiresan, S; Meigs, JB; Ehm, MG; Wareham, NJ; Waterworth, DM (2016-06)
      Regulatory authorities have indicated that new drugs to treat type 2 diabetes (T2D) should not be associated with an unacceptable increase in cardiovascular risk. Human genetics may be able to guide development of antidiabetic ...